Business Context and Reporting Period
This Form 8-K Current Report is filed by Miragen Therapeutics, Inc. (trading symbol: MGEN) for the reporting period ending October 31, 2019. The Company is a Delaware corporation listed on The Nasdaq Capital Market and is classified as an emerging growth company. The filing primarily addresses a material definitive agreement regarding a stock purchase and a notice of non-compliance with Nasdaq listing rules.
Key Financial Metrics and Capital Activity
The filing details a specific equity financing event rather than providing comprehensive period-over-period financial statements (e.g., revenue, net income, or operating cash flow).
- Equity Issuance: On October 31, 2019, the Company issued 606,364 shares of common stock.
- Gross Proceeds: The aggregate purchase price was $500,000.
- Net Proceeds: Expected net proceeds after expenses are approximately $475,000.
- Use of Proceeds: Funds are designated for the Company's SOLAR clinical trial.
- Debt and Liquidity: The filing text does not provide specific values for total debt, cash balances, or liquidity ratios.
Material Changes and Corporate Actions
Two significant events occurred during the reporting period:
- Assignment of Purchase Agreement: On October 28, 2019, the Company entered into an Assignment Agreement. The Leukemia & Lymphoma Society, Inc. (LLS) assigned its rights and obligations under a 2018 Common Stock Purchase Agreement to LLS TAP Miragen, LLC. The Assignee agreed to be bound by the original terms.
- Nasdaq Non-Compliance Notice: On October 28, 2019, the Company received notice from Nasdaq that its common stock failed to meet Listing Rule 5550(a)(2) because the minimum bid price remained below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Contingencies
Delisting Risk and Compliance: The Company has a 180-day compliance period (until April 27, 2020) to regain compliance with the minimum bid price requirement. To comply, the stock must close at $1.00 or more for 10 consecutive business days. If the Company fails to regain compliance, it may be eligible for an additional compliance period by meeting market value standards and potentially effecting a reverse stock split. Failure to cure the deficiency could result in delisting.
Management Commentary and Risks: Management intends to monitor the bid price and consider options, including a reverse stock split, to resolve the deficiency. The filing explicitly states there is no assurance the Company will maintain its listing. Delisting could materially impair liquidity, reduce the market price of the stock, and adversely affect the Company's ability to raise capital.
Unusual Items: The equity issuance was conducted as an unregistered sale exempt under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with the Assignee representing it is an accredited investor.
Investor Verification Checklist
- Verify the current trading price of MGEN to assess the likelihood of meeting the $1.00 minimum bid price requirement within the 180-day window.
- Review the full text of the Assignment Agreement (Exhibit 10.1) and the original Purchase Agreement (Exhibit 10.2 to the Nov 7, 2018 10-Q) for specific obligations of LLS TAP Miragen, LLC.
- Monitor future filings for announcements regarding a potential reverse stock split or additional capital raises to address the delisting risk.
- Confirm the status and funding requirements of the SOLAR clinical trial to understand the utilization of the $475,000 net proceeds.